Literature DB >> 31412233

RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES.

Barbara H Braffett, Gayle M Lorenzi, Catherine C Cowie, Xiaoyu Gao, Kathleen E Bainbridge, Karen J Cruickshanks, John R Kramer, Rose A Gubitosi-Klug, Mary E Larkin, Annette Barnie, John M Lachin, David S Schade.   

Abstract

Objective: Studies have demonstrated that glycated hemoglobin (HbA1c) is a significant predictor of hearing impairment in type 1 diabetes. We identified additional factors associated with hearing impairment in participants with type 1 diabetes from the Diabetes Control and Complications Trial and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.
Methods: A total of 1,150 DCCT/EDIC participants were recruited for the Hearing Study. A medical history, physical measurements, and a self-administered hearing questionnaire were obtained. Audiometry was performed by study-certified personnel and assessed centrally. Logistic regression models assessed the association of risk factors and comorbidities with speech- and high-frequency hearing impairment.
Results: Mean age was 55 ± 7 years, duration of diabetes 34 ± 5 years, and DCCT/EDIC HbA1c 7.9 ± 0.9% (63 mmol/mol). In multivariable models, higher odds of speech-frequency impairment were significantly associated with older age, higher HbA1c, history of noise exposure, male sex, and higher triglycerides. Higher odds of high-frequency impairment were associated with older age, male sex, history of noise exposure, higher skin intrinsic florescence (SIF) as a marker of tissue glycation, higher HbA1c, nonprofessional/nontechnical occupations, sedentary activity, and lower low-density-lipoprotein cholesterol. Among participants who previously completed computed tomography and carotid ultrasonography, coronary artery calcification (CAC) >0 and carotid intima-medial thickness were significantly associated with high-but not speech-frequency impairment.
Conclusion: Consistent with previous reports, male sex, age, several metabolic factors, and noise exposure are independently associated with hearing impairment. The association with SIF further emphasizes the importance of glycemia-as a modifiable risk factor-over time. In addition, the macrovascular contribution of CAC is novel and important. Abbreviations: AER = albumin excretion rate; CAC = coronary artery calcification; CVD = cardiovascular disease; DCCT/EDIC = Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications; eGFR = estimated glomerular filtration rate; ETDRS = Early Treatment Diabetic Retinopathy Study; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; IMT = intima-media thickness; LDL = low-density lipoprotein; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; SIF = skin intrinsic fluorescence; T1D = type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31412233      PMCID: PMC7217092          DOI: 10.4158/EP-2019-0193

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  42 in total

1.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 2.  Aminoglycoside antibiotics.

Authors:  A Forge; J Schacht
Journal:  Audiol Neurootol       Date:  2000 Jan-Feb       Impact factor: 1.854

3.  Hearing Impairment Prevalence and Associated Risk Factors in the Hispanic Community Health Study/Study of Latinos.

Authors:  Karen J Cruickshanks; Sumitrajit Dhar; Elizabeth Dinces; Robert C Fifer; Franklyn Gonzalez; Gerardo Heiss; Howard J Hoffman; David J Lee; Marilyn Newhoff; Laura Tocci; Peter Torre; Ted S Tweed
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-07       Impact factor: 6.223

4.  The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study.

Authors:  Scott D Nash; Karen J Cruickshanks; Ronald Klein; Barbara E K Klein; F Javier Nieto; Guan H Huang; James S Pankow; Theodore S Tweed
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-02-21

5.  Longitudinal study of pure-tone thresholds in older persons.

Authors:  Fu-Shing Lee; Lois J Matthews; Judy R Dubno; John H Mills
Journal:  Ear Hear       Date:  2005-02       Impact factor: 3.570

6.  Lipid and C-reactive protein levels as risk factors for hearing loss in older adults.

Authors:  Annie N Simpson; Lois J Matthews; Judy R Dubno
Journal:  Otolaryngol Head Neck Surg       Date:  2013-01-15       Impact factor: 3.497

7.  The impact of hearing loss on quality of life in older adults.

Authors:  Dayna S Dalton; Karen J Cruickshanks; Barbara E K Klein; Ronald Klein; Terry L Wiley; David M Nondahl
Journal:  Gerontologist       Date:  2003-10

8.  Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up.

Authors:  Prahlad Duggal; Malay Sarkar
Journal:  BMC Ear Nose Throat Disord       Date:  2007-11-12

9.  Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.

Authors:  John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

Review 10.  Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.

Authors:  Bernardina T Fokkens; Andries J Smit
Journal:  Glycoconj J       Date:  2016-06-10       Impact factor: 2.916

View more
  1 in total

1.  Effective Hearing Loss Screening in Primary Care: The Early Auditory Referral-Primary Care Study.

Authors:  Philip Zazove; Melissa A Plegue; Michael M McKee; Melissa DeJonckheere; Paul R Kileny; Lauren S Schleicher; Lee A Green; Ananda Sen; Mary E Rapai; Elie Mulhem
Journal:  Ann Fam Med       Date:  2020-11       Impact factor: 5.166

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.